Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
37 stopped studies mapped to Rectal Adenocarcinoma and descendants · 89% state a reason
Over the 37 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06929338 | xDRIVE in Metastatic Colorectal Cancer | — | withdrawn | Apr 16, 2025 | First Ascent Biomedical Inc. | Unable to finalize study agreements | Other (stated, no rule matched) |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating… | Phase 2 | terminated | Jun 6, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or… | Phase 1 | terminated | Oct 3, 2024 | Accent Therapeutics | The study was terminated by sponsor based on the adverse event profile. | Safety / toxicity |
| NCT03765736 | Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal… | — | terminated | Dec 5, 2018 | Academic and Community Cancer Research United | Low accrual | Enrollment / accrual |
| NCT04406857 | Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy… | Phase 1 | terminated | May 29, 2020 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT06575725 | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the… | Phase 2 | withdrawn | Aug 28, 2024 | City of Hope Medical Center | Abandoned 9/23/24 | Other (stated, no rule matched) |
| NCT05356897 | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive… | Phase 2 | withdrawn | May 2, 2022 | Academic and Community Cancer Research United | no sites were regulatory ready and the SC took the study to a different group. | Other (stated, no rule matched) |
| NCT03300544 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating… | Phase 1 | terminated | Oct 3, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal… | Phase 2 | terminated | Jul 19, 2018 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating… | Phase 2 | terminated | Sep 3, 2008 | M.D. Anderson Cancer Center | The trial was stopped early because there was only one patient with pCR among the first 15 patients… | Other (stated, no rule matched) |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III… | Phase 3 | terminated | Mar 17, 2006 | ECOG-ACRIN Cancer Research Group | The study was terminated before reaching its accrual goal due to slow accrual. | Enrollment / accrual |
| NCT04044430 | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E… | Phase 1 | terminated | Aug 5, 2019 | University of California, San Francisco | Sponsor funding | Funding |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Phase 2 | terminated | Oct 3, 2018 | Abramson Cancer Center at Penn Medicine | Terminated due to slow enrollment and lack of efficacy | Efficacy / futility |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From… | Phase 1 | terminated | Jan 27, 2011 | Fox Chase Cancer Center | This study was closed early by the DSMB due to increased toxicity. | Safety / toxicity |
| NCT04418895 | Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | Phase 2 | withdrawn | Jun 5, 2020 | UNC Lineberger Comprehensive Cancer Center | lack of resources | Other (stated, no rule matched) |
| NCT02319304 | Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed…(GCC 1314) | Phase 2 | terminated | Dec 18, 2014 | University of Maryland, Baltimore | Slow accrual, PI left instituion | Investigator |
| NCT02425683 | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of… | Phase 2 | terminated | Apr 24, 2015 | US Oncology Research | insufficient accrual | Enrollment / accrual |
| NCT00397878 | AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer… | Phase 2 | terminated | Nov 10, 2006 | National Cancer Institute (NCI) | The study was terminated after all enrolled participants progressed. | Enrollment / accrual |
| NCT02233595 | Evaluation of Rectal Cancer Treatment Response Using PET/MRI(Rectal PET/MRI) | — | terminated | Sep 8, 2014 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT03527784 | Prestoma-Trial for Parastomal Hernia Prevention | N/A | terminated | May 17, 2018 | University of Oulu | Parastomal Parietex withdrawn from market by the manufacturer. | Drug supply |
| NCT01197664 | Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer… | Phase 1 | terminated | Sep 9, 2010 | Wake Forest University Health Sciences | Study terminated due to funding issues | Funding |
| NCT01887509 | Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to…(TRaMA) | N/A | terminated | Jun 27, 2013 | IHU Strasbourg | Difficulties with patients recruitment, study acceptance and protocol implementation. | Enrollment / accrual |
| NCT02110953 | Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal… | Phase 1 | terminated | Apr 10, 2014 | Fox Chase Cancer Center | IRB study closure by investigator due to low enrollment | Investigator |
| NCT01934179 | Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal… | — | terminated | Sep 4, 2013 | Fox Chase Cancer Center | Low Accrual Rate | Enrollment / accrual |
| NCT02407561 | Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein… | — | terminated | Apr 3, 2015 | Castle Biosciences Incorporated | Futility - unable to secure sites and samples for participation | Efficacy / futility |
| NCT01270438 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients… | Phase 2 | withdrawn | Jan 5, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02046538 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | Phase 2 | withdrawn | Jan 27, 2014 | Weill Medical College of Cornell University | Investigator terminated due to funding issues | Investigator |
| NCT02287727 | Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have… | Phase 2 | withdrawn | Nov 11, 2014 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Oct 14, 2015 | Roswell Park Cancer Institute | drug supply issues | Drug supply |
| NCT01198535 | Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer | Phase 1 | terminated | Sep 10, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02235324 | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in… | Phase 2 | withdrawn | Sep 9, 2014 | University of Southern California | Lack of funding | Funding |
| NCT00835679 | Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That… | Early Phase 1 | terminated | Feb 4, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01403103 | Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer | Early Phase 1 | withdrawn | Jul 27, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT00002796 | Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced… | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00070122 | Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced,… | Phase 3 | terminated | Oct 7, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT01619696 | Prospective Pilot Study of Multimodal Radiological Evaluation Feasibility During… | Phase 2 | terminated | Jun 14, 2012 | University Hospital, Toulouse | Insufficient recruitment | Enrollment / accrual |
| NCT00052585 | Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent… | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Sep 2, 2026source: clinicaltrials